Gilead Wins FDA Accelerated Approval for Livdelzi in PBC, Also Approves Hepcludex

Gilead Sciences (NasdaqGS:GILD) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC), a rare autoimmune liver disease. The FDA also approved Hepcludex (bulevirtide) for hepatitis delta virus (HDV), a severe viral liver infection.

The Products

Livdelzi targets PPAR-delta receptors, reducing inflammation and improving liver function in PBC patients. The Phase 3 IDEAL trial showed the drug achieves normalization of alkaline phosphatase (ALP), a key biomarker for liver damage. Hepcludex is the first approved treatment for HDV, blocking viral entry into liver cells.

Pricing and Availability

Gilead has not yet disclosed pricing or commercial launch timelines for either drug. Additional details on access and pricing are expected in the coming weeks.

Competition

In the PBC market, Gilead faces competition from Ocaliva (Intercept Pharmaceuticals), which has safety limitations. Other pipeline candidates include elafibranor from Ipsen. In the HDV market, Hepcludex is currently the only approved therapy, giving it a clear competitive advantage.

Potential Impact on the Company

These approvals strengthen Gilead's position in liver disease, a strategic area alongside its antiviral portfolio. The new drugs are expected to diversify Gilead's revenue and reduce reliance on HIV treatments.